Spinout Active LTD

Company profile

Odin Medical Limited

UK company 11563083, incorporated on 11 September 2018.

Odin Medical Limited is a UK company with status Active founded in 2018 based in London.

Company number
11563083
Incorporated
11 Sep 2018
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
11 September 2018

Company number 11563083

Verify at Companies House
Legal name
ODIN MEDICAL LIMITED
Company type
Private Limited Company
Region
London
Registered address
74 RIVINGTON STREET
LONDON
ENGLAND
EC2A 3AY
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

21 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

07 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

11 Sep
2018

Incorporated

Inception

Company registered at Companies House

Spinout profile

1 entry

Company description

Odin specialises in developing computer aided diagnostic solutions for endoscopic diagnostic and therapeutic procedures.

Project impact

Too early to report key achievements.

ODIN MEDICAL LIMITED
2018

Public funding

4 awards
First funded
2019
Funded years
2019, 2020, 2021, 2022
Age at first award
0 years

Projects

2022 Collaborative R&D Lead participant

RESECT-AI: Reliable Estimations for Safer Endoscopic Cancer Therapy with Artificial Intelligence

1 Jun 2022 to 31 May 2024

Awarded
£417,127
Total cost £595,896

Colorectal cancer (CRC) has the 4th highest incidence of all cancers in the UK and the 3rd highest worldwide. 1.4m new cases and 0.7m related deaths are reported each year. The incidence and number of deaths is estimated to rise by 60% by 2030\. The current global economic impact is estimated to be £100Bn. There are 230k people living in the UK with CRC, ...

2022 Collaborative R&D Lead participant

B-Linc: Biomarkers for Lesion Images Non-diminutive and Complex

1 Apr 2022 to 31 Mar 2023

Awarded
£341,642
Total cost £488,060

Colorectal cancer (CRC) is a worldwide disease. There are 1.3m new cases and 0.7m related deaths are reported each year. In the UK, CRC is the second most common cause of cancer related deaths with 41k new incidents and over 16k related deaths reported each year. 230k people are living in the UK with CRC. Colonoscopy is critical tools in the detection and...

2021 Collaborative R&D Lead participant

CADDIE - Resilience

1 Dec 2021 to 31 Jan 2022

Awarded
£99,361
Total cost £99,361

Colorectal cancer (CRC) is a worldwide disease with 1.3m new cases and 0.7m related deaths reported each year and estimated global economic impact approaching £100 Billion per year. In the UK, CRC is the second most common cause of cancer related deaths, 41k new incidents and over 16k related deaths are reported each year. 230k people are living in the UK...

2020 Feasibility Studies Lead participant

CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy

1 Jun 2020 to 31 Mar 2021

Awarded
£185,000
Total cost £185,000

no public description

2019 Collaborative R&D Lead participant

CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy

1 Apr 2019 to 31 Mar 2022

Awarded
£328,720
Total cost £469,600

Colorectal cancer (CRC) is a worldwide disease with 1.3m new cases and 0.7m related deaths reported each year and estimated global economic impact approaching £100 Billion per year. In the UK, CRC is the second most common cause of cancer related deaths, 41k new incidents and over 16k related deaths are reported each year. 230k people are living in the UK...

Product types

Collaborative R&D Feasibility Studies